NTR

Navigating Nutrien – A Quick Overview

It's been a great morning session for Nutrien investors, who saw their shares rise 1.7% to a price of $53.37 per share. At these higher prices, is the company still fairly valued? If you are thinking about investing, make sure to check the company's fundamentals before making a decision.

The Market May Be Undervaluing Nutrien's Earnings and Assets:

Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Retail, Potash, Nitrogen, and Phosphate. The company belongs to the Industrials sector, which has an average price to earnings (P/E) ratio of 22.19 and an average price to book (P/B) ratio of 4.06. In contrast, Nutrien has a trailing 12 month P/E ratio of 21.1 and a P/B ratio of 1.05.

When we divide Nutrien's P/E ratio by its expected EPS growth rate of the next five years, we obtain its PEG ratio of -0.58. Since it's negative, the company has negative growth expectations, and most investors will probably avoid the stock unless it has an exceptionally low P/E and P/B ratio.

Wider Gross Margins Than the Industry Average of 13.23%:

2017 2018 2019 2020 2021 2022
Revenue (M) $4,547 $19,636 $20,084 $20,908 $27,712 $37,884
Gross Margins 15% 27% 27% 25% 34% 41%
Net Margins 7% 18% 5% 2% 11% 20%
Net Income (M) $327 $3,573 $992 $459 $3,179 $7,687
Free Cash Flow (M) $1,225 $2,052 $3,665 $3,323 $3,886 $8,110
Total Debt (M) $3,711 $7,579 $8,553 $10,047 $7,521 $8,040
Net Debt / EBITDA 3.99 2.62 2.15 2.97 1.04 0.56
Current Ratio 2.07 1.4 1.17 1.35 1.11 1.14

Nutrien has generally positive cash flows, wider gross margins than its peer group, and healthy leverage levels. Furthermore, Nutrien has just enough current assets to cover current liabilities, as shown by its current ratio of 1.14.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS